Hospital
Lewis-Gale Medical Center, LLC
Lewis-Gale Medical Center, LLC was paid $51.85M by Medicaid between Jan 2018 and Dec 2024, across 297 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoLEWIS-GALE MEDICAL CENTER, LLC
SALEM, VA 24153
SALEM, VA 24153
33aNPI1619914785assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$51.85M
24GClaims1,288,362
24DCodes billed297
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#14 of 80
Median peer was paid$14.69M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 115,625 | $2.64M | |
| 2019 | 171,219 | $4.95M | |
| 2020 | 152,954 | $5.57M | |
| 2021 | 201,105 | $7.56M | |
| 2022 | 216,243 | $9.42M | |
| 2023 | 243,515 | $11.37M | |
| 2024incomplete | 187,701 | $10.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 95,799 | 82,972 | $17.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 51,537 | 43,044 | $8.27M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.3% | 23,246 | 21,369 | $4.32M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 10,554 | 9,446 | $1.93M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 10,719 | 9,204 | $1.67M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 4,893 | 4,315 | $1.52M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.8% | 7,990 | 7,494 | $1.46M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 8,442 | 7,378 | $1.39M |
| G0378 | Hospital observation service, per hour | 2.5% | 10,637 | 5,850 | $1.28M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.6% | 1,386 | 1,238 | $819K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 2,314 | 2,006 | $788K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 15,345 | 12,633 | $699K |
285 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.3% | 2,836 | $656K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 2,200 | $621K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 3,408 | $578K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 11,591 | $452K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,043 | $449K |
| 93458 | <1% | 243 | $403K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,425 | $383K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,073 | $307K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,007 | $280K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,362 | $243K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 867 | $243K |
| 10060 | <1% | 1,605 | $235K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,382 | $234K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,526 | $234K |
| 12001 | <1% | 982 | $222K | |
| 80053 | Comprehensive metabolic panel | <1% | 70,764 | $219K |
| 93017 | <1% | 1,791 | $205K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 11,314 | $202K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,050 | $197K |
| 93971 | <1% | 1,818 | $186K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 38,155 | $178K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,774 | $168K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 850 | $146K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 422 | $125K |
| 76830 | Ultrasound, transvaginal | <1% | 1,558 | $124K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,533 | $108K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,043 | $103K |
| 97162 | <1% | 1,561 | $97K | |
| 93976 | <1% | 2,127 | $96K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,510 | $92K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,130 | $87K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,589 | $76K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 469 | $74K |
| 71045 | Radiologic examination, chest; single view | <1% | 32,296 | $74K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,417 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,694 | $72K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 41 | $71K |
| 76536 | <1% | 675 | $69K | |
| 85027 | <1% | 85,632 | $68K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,837 | $64K |
| 12011 | <1% | 267 | $63K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,731 | $56K |
| 70491 | <1% | 254 | $47K | |
| 97166 | <1% | 710 | $47K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,874 | $46K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 903 | $45K |
| 70496 | <1% | 220 | $45K | |
| 97163 | <1% | 432 | $43K | |
| 72100 | <1% | 3,862 | $43K | |
| 29125 | <1% | 484 | $43K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,876 | $42K |
| 94060 | <1% | 866 | $42K | |
| 87510 | <1% | 5,161 | $41K | |
| 74018 | <1% | 3,102 | $38K | |
| 97167 | <1% | 489 | $38K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,053 | $37K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 158 | $36K |
| 76770 | <1% | 266 | $34K | |
| 87040 | <1% | 5,918 | $34K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 173 | $33K |
| 94729 | <1% | 775 | $32K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,368 | $32K |
| 90715 | <1% | 2,025 | $31K | |
| 70486 | <1% | 652 | $29K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,597 | $28K |
| 76642 | <1% | 231 | $25K | |
| 84484 | <1% | 20,606 | $24K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 161 | $24K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 656 | $23K |
| 12002 | <1% | 115 | $23K | |
| 97161 | <1% | 337 | $23K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,070 | $22K |
| 87660 | <1% | 5,161 | $22K | |
| 93246 | <1% | 241 | $20K | |
| 71250 | <1% | 257 | $19K | |
| 83880 | <1% | 3,083 | $18K | |
| 85379 | <1% | 5,160 | $18K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 164 | $18K |
| 94726 | <1% | 574 | $18K | |
| 76775 | <1% | 235 | $16K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 873 | $15K |
| 70498 | <1% | 162 | $15K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 28 | $14K |
| 72050 | <1% | 813 | $14K | |
| 84703 | <1% | 20,768 | $14K | |
| 73030 | <1% | 2,977 | $13K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 111 | $12K |
| 76870 | <1% | 143 | $11K | |
| 73630 | <1% | 3,719 | $10K | |
| 93970 | <1% | 90 | $10K | |
| 74022 | <1% | 836 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,689 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,370 | $9K |
| 71101 | <1% | 759 | $9K | |
| 59025 | Fetal non-stress test | <1% | 45 | $9K |
| 87480 | <1% | 5,146 | $8K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,073 | $8K |
| 85014 | <1% | 1,268 | $8K | |
| 73610 | <1% | 3,497 | $8K | |
| 71271 | <1% | 93 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26,499 | $8K |
| 73130 | <1% | 2,794 | $7K | |
| 97165 | <1% | 200 | $7K | |
| 73560 | <1% | 2,316 | $7K | |
| 96376 | <1% | 2,563 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,646 | $6K |
| 86850 | <1% | 2,980 | $6K | |
| 64400 | <1% | 12 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 41 | $6K |
| 83690 | <1% | 17,207 | $6K | |
| 97116 | <1% | 395 | $6K | |
| 87088 | <1% | 9,386 | $6K | |
| 73110 | <1% | 1,948 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 26,894 | $5K |
| 80061 | Lipid panel | <1% | 1,776 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,298 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,295 | $5K |
| 72141 | <1% | 27 | $5K | |
| 81025 | <1% | 12,462 | $5K | |
| 81001 | <1% | 28,034 | $5K | |
| 62323 | <1% | 15 | $5K | |
| 83735 | <1% | 9,472 | $5K | |
| 85610 | <1% | 10,204 | $4K | |
| 83605 | <1% | 5,460 | $4K | |
| 73502 | <1% | 1,381 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 24,131 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 11,360 | $4K |
| 80074 | <1% | 434 | $4K | |
| 72040 | <1% | 631 | $4K | |
| 87070 | <1% | 11,124 | $4K | |
| 86900 | <1% | 3,935 | $4K | |
| 73562 | <1% | 1,158 | $4K | |
| 74174 | <1% | 31 | $4K | |
| 82728 | <1% | 1,096 | $3K | |
| 82565 | <1% | 1,462 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 82 | $3K |
| 72131 | <1% | 43 | $3K | |
| 93880 | <1% | 48 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,468 | $3K |
| 86901 | <1% | 3,937 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,502 | $3K |
| C1769 | Guide wire | <1% | 2,332 | $3K |
| 0296T | <1% | 118 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,579 | $3K |
| 80076 | <1% | 574 | $3K | |
| 15853 | <1% | 74 | $3K | |
| 95819 | <1% | 13 | $3K | |
| 72070 | <1% | 479 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 103 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 29,422 | $2K |
| 73090 | <1% | 734 | $2K | |
| 82077 | <1% | 4,934 | $2K | |
| 81003 | <1% | 19,897 | $2K | |
| 76937 | <1% | 118 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,135 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,836 | $2K |
| 73590 | <1% | 876 | $2K | |
| 84702 | <1% | 4,063 | $2K | |
| 85730 | <1% | 5,669 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,346 | $2K |
| 84112 | <1% | 286 | $2K | |
| 82607 | <1% | 519 | $2K | |
| 73080 | <1% | 713 | $2K | |
| 87147 | <1% | 1,755 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,562 | $2K |
| 80143 | <1% | 541 | $1K | |
| 87077 | <1% | 2,831 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,279 | $1K |
| 82378 | <1% | 560 | $1K | |
| 36591 | <1% | 101 | $1K | |
| 73140 | <1% | 922 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,781 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,532 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 355 | $1K |
| 84100 | <1% | 2,402 | $1K | |
| 87186 | <1% | 3,801 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,557 | $986.48 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,634 | $972.42 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 18,020 | $926.89 |
| A9270 | Non-covered item or service | <1% | 9,690 | $924.00 |
| 73564 | <1% | 56 | $846.55 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,024 | $843.44 |
| 74021 | <1% | 41 | $835.68 | |
| 87205 | <1% | 1,184 | $828.01 | |
| 85652 | <1% | 890 | $809.60 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 68 | $727.20 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,068 | $714.64 |
| 87807 | <1% | 5,499 | $692.43 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 4,657 | $661.82 |
| 87210 | <1% | 1,994 | $638.21 | |
| 80047 | <1% | 548 | $584.39 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 576 | $571.52 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,407 | $549.30 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 791 | $533.95 |
| S0028 | Injection, famotidine, 20 mg | <1% | 808 | $495.59 |
| 80179 | <1% | 418 | $488.24 | |
| 84145 | <1% | 26 | $434.62 | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 310 | $428.60 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,600 | $415.96 |
| 86140 | <1% | 155 | $404.18 | |
| 86592 | <1% | 77 | $403.46 | |
| 82550 | <1% | 909 | $397.18 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 288 | $396.23 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,711 | $382.91 |
| 87899 | <1% | 140 | $379.20 | |
| 93922 | <1% | 13 | $372.53 | |
| 82274 | <1% | 611 | $351.81 | |
| 84439 | <1% | 171 | $351.77 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 915 | $336.72 |
| 82803 | <1% | 446 | $304.95 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 394 | $265.11 |
| 87522 | Neg quan hep c or qual rna | <1% | 15 | $261.64 |
| J3490 | Unclassified drugs | <1% | 2,716 | $237.87 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,496 | $232.22 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,063 | $220.97 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 262 | $218.74 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,891 | $200.98 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,110 | $185.98 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,998 | $180.45 |
| 73120 | <1% | 12 | $159.11 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 537 | $153.03 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 52 | $151.35 |
| 82150 | <1% | 1,063 | $150.69 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,042 | $142.22 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,387 | $140.34 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,530 | $132.98 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 31 | $129.66 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,393 | $122.24 |
| 86703 | <1% | 85 | $105.98 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 258 | $82.28 |
| 86141 | <1% | 51 | $78.91 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,398 | $73.90 |
| 82570 | <1% | 100 | $68.28 | |
| 73552 | <1% | 25 | $62.31 | |
| 72170 | <1% | 88 | $61.95 | |
| 76000 | <1% | 64 | $59.45 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 129 | $49.83 |
| 83540 | <1% | 42 | $44.10 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,029 | $42.37 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 490 | $37.75 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 676 | $35.21 |
| 72072 | <1% | 30 | $34.78 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 453 | $34.38 |
| 84156 | <1% | 54 | $27.33 | |
| 82010 | <1% | 308 | $22.74 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,696 | $21.95 |
| 82746 | <1% | 35 | $19.74 | |
| 82947 | <1% | 28 | $18.61 | |
| 82435 | <1% | 15 | $16.24 | |
| 86706 | <1% | 13 | $16.08 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 21 | $14.98 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 125 | $11.02 |
| 86308 | <1% | 40 | $10.92 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 194 | $10.38 |
| 84295 | <1% | 15 | $8.13 | |
| 84132 | <1% | 18 | $8.13 | |
| 83550 | <1% | 25 | $7.64 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 24 | $7.51 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,360 | $4.17 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 77 | $3.77 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 34 | $3.05 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 94 | $2.62 |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 66 | $0.69 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 261 | $0.47 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 343 | $0.46 |
| S4991 | Nicotine patches, non-legend | <1% | 1,045 | $0.23 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 82 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 222 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 193 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 25 | $0.00 |
| 29515 | 0% | 27 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 50 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 154 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 38 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 102 | $0.00 |
| 73060 | 0% | 14 | $0.00 | |
| 72126 | 0% | 14 | $0.00 | |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 18 | $0.00 |
| 73620 | 0% | 19 | $0.00 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 13 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 15 | $0.00 |
| 73660 | 0% | 12 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 21 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 46 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREYNOLDS, ANGELA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Columbia-Alleghany Regional Hospital INC | Low Moor, VA | $9.82M |
| Lewis-Gale Medical Center, LLC | Cave Spring, VA | $1.17M |
| Lewisgale Medical Center, LLC | Roanoke, VA | $413K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.